The global market for Group A and Group C Meningococcal Polysaccharide Vaccine was valued at US$ 318 million in the year 2024 and is projected to reach a revised size of US$ 472 million by 2031, growing at a CAGR of 5.9% during the forecast period.

Group A and Group C Meningococcal Polysaccharide Vaccine Market

After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.

Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Group A and Group C Meningococcal Polysaccharide Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Group A and Group C Meningococcal Polysaccharide Vaccine.

The Group A and Group C Meningococcal Polysaccharide Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Group A and Group C Meningococcal Polysaccharide Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Group A and Group C Meningococcal Polysaccharide Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Group A and Group C Meningococcal Polysaccharide Vaccine Market Report

Report Metric	Details
Report Name	Group A and Group C Meningococcal Polysaccharide Vaccine Market
Accounted market size in year	US$ 318 million
Forecasted market size in 2031	US$ 472 million
CAGR	5.9%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Class 1 Vaccine Class II Vaccine
Segment by Application	Hospital Clinic
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Walvax, Lanzhou Institute of Biological Products, AIM Bio, Sanofi Pasteur, GSK, Hualan Bio, ZFSW, Changsheng, Kanghua Bio
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Group A and Group C Meningococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Group A and Group C Meningococcal Polysaccharide Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Group A and Group C Meningococcal Polysaccharide Vaccine Market growing?

Ans: The Group A and Group C Meningococcal Polysaccharide Vaccine Market witnessing a CAGR of 5.9% during the forecast period 2025-2031.

What is the Group A and Group C Meningococcal Polysaccharide Vaccine Market size in 2031?

Ans: The Group A and Group C Meningococcal Polysaccharide Vaccine Market size in 2031 will be US$ 472 million.

Who are the main players in the Group A and Group C Meningococcal Polysaccharide Vaccine Market report?

Ans: The main players in the Group A and Group C Meningococcal Polysaccharide Vaccine Market are Walvax, Lanzhou Institute of Biological Products, AIM Bio, Sanofi Pasteur, GSK, Hualan Bio, ZFSW, Changsheng, Kanghua Bio

What are the Application segmentation covered in the Group A and Group C Meningococcal Polysaccharide Vaccine Market report?

Ans: The Applications covered in the Group A and Group C Meningococcal Polysaccharide Vaccine Market report are Hospital, Clinic

What are the Type segmentation covered in the Group A and Group C Meningococcal Polysaccharide Vaccine Market report?

Ans: The Types covered in the Group A and Group C Meningococcal Polysaccharide Vaccine Market report are Class 1 Vaccine, Class II Vaccine

1 Group A and Group C Meningococcal Polysaccharide Vaccine Market Overview

1.1 Product Definition

1.2 Group A and Group C Meningococcal Polysaccharide Vaccine by Type

1.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Value Comparison by Type (2024 VS 2031)

1.2.2 Class 1 Vaccine

1.2.3 Class II Vaccine

1.3 Group A and Group C Meningococcal Polysaccharide Vaccine by Application

1.3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.4 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size Estimates and Forecasts

1.4.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue 2020-2031

1.4.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales 2020-2031

1.4.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Group A and Group C Meningococcal Polysaccharide Vaccine Market Competition by Manufacturers

2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2020-2025)

2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Group A and Group C Meningococcal Polysaccharide Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, Product Type & Application

2.7 Global Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, Date of Enter into This Industry

2.8 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Competitive Situation and Trends

2.8.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Group A and Group C Meningococcal Polysaccharide Vaccine Players Market Share by Revenue

2.8.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Scenario by Region

3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region: 2020-2031

3.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region: 2020-2025

3.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region: 2026-2031

3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region: 2020-2031

3.3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region: 2020-2025

3.3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region: 2026-2031

3.4 North America Group A and Group C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country

3.4.1 North America Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)

3.4.3 North America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country

3.5.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)

3.5.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Region

3.6.1 Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2020-2031)

3.6.3 Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country

3.7.1 Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)

3.7.3 Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2031)

3.8.3 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2031)

4.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025)

4.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2026-2031)

4.1.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2031)

4.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Type (2020-2031)

4.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Type (2020-2025)

4.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Type (2026-2031)

4.2.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2020-2031)

4.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Price by Type (2020-2031)

5 Segment by Application

5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2031)

5.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025)

5.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2026-2031)

5.1.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2031)

5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Application (2020-2031)

5.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Application (2020-2025)

5.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Application (2026-2031)

5.2.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2020-2031)

5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Walvax

6.1.1 Walvax Company Information

6.1.2 Walvax Description and Business Overview

6.1.3 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio

6.1.5 Walvax Recent Developments/Updates

6.2 Lanzhou Institute of Biological Products

6.2.1 Lanzhou Institute of Biological Products Company Information

6.2.2 Lanzhou Institute of Biological Products Description and Business Overview

6.2.3 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio

6.2.5 Lanzhou Institute of Biological Products Recent Developments/Updates

6.3 AIM Bio

6.3.1 AIM Bio Company Information

6.3.2 AIM Bio Description and Business Overview

6.3.3 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.3.4 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio

6.3.5 AIM Bio Recent Developments/Updates

6.4 Sanofi Pasteur

6.4.1 Sanofi Pasteur Company Information

6.4.2 Sanofi Pasteur Description and Business Overview

6.4.3 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio

6.4.5 Sanofi Pasteur Recent Developments/Updates

6.5 GSK

6.5.1 GSK Company Information

6.5.2 GSK Description and Business Overview

6.5.3 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.5.4 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio

6.5.5 GSK Recent Developments/Updates

6.6 Hualan Bio

6.6.1 Hualan Bio Company Information

6.6.2 Hualan Bio Description and Business Overview

6.6.3 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio

6.6.5 Hualan Bio Recent Developments/Updates

6.7 ZFSW

6.7.1 ZFSW Company Information

6.7.2 ZFSW Description and Business Overview

6.7.3 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.7.4 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio

6.7.5 ZFSW Recent Developments/Updates

6.8 Changsheng

6.8.1 Changsheng Company Information

6.8.2 Changsheng Description and Business Overview

6.8.3 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio

6.8.5 Changsheng Recent Developments/Updates

6.9 Kanghua Bio

6.9.1 Kanghua Bio Company Information

6.9.2 Kanghua Bio Description and Business Overview

6.9.3 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolio

6.9.5 Kanghua Bio Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Group A and Group C Meningococcal Polysaccharide Vaccine Industry Chain Analysis

7.2 Group A and Group C Meningococcal Polysaccharide Vaccine Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Group A and Group C Meningococcal Polysaccharide Vaccine Production Mode & Process Analysis

7.4 Group A and Group C Meningococcal Polysaccharide Vaccine Sales and Marketing

7.4.1 Group A and Group C Meningococcal Polysaccharide Vaccine Sales Channels

7.4.2 Group A and Group C Meningococcal Polysaccharide Vaccine Distributors

7.5 Group A and Group C Meningococcal Polysaccharide Vaccine Customer Analysis

8 Group A and Group C Meningococcal Polysaccharide Vaccine Market Dynamics

8.1 Group A and Group C Meningococcal Polysaccharide Vaccine Industry Trends

8.2 Group A and Group C Meningococcal Polysaccharide Vaccine Market Drivers

8.3 Group A and Group C Meningococcal Polysaccharide Vaccine Market Challenges

8.4 Group A and Group C Meningococcal Polysaccharide Vaccine Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Walvax

Lanzhou Institute of Biological Products

List of Tables

Table 1. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Competitive Situation by Manufacturers in 2024

Table 4. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Group A and Group C Meningococcal Polysaccharide Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Group A and Group C Meningococcal Polysaccharide Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Group A and Group C Meningococcal Polysaccharide Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Group A and Group C Meningococcal Polysaccharide Vaccine as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2020-2025) & (K Units)

Table 18. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2020-2025)

Table 19. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2026-2031) & (K Units)

Table 20. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2026-2031)

Table 21. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2020-2025)

Table 23. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2026-2031)

Table 25. North America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025) & (K Units)

Table 27. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2026-2031) & (K Units)

Table 28. North America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025) & (K Units)

Table 32. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2026-2031) & (K Units)

Table 33. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units) by Type (2020-2025)

Table 51. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units) by Type (2026-2031)

Table 52. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)

Table 53. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2026-2031)

Table 54. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2020-2025)

Table 57. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2026-2031)

Table 58. Global Group A and Group C Meningococcal Polysaccharide Vaccine Price (US$/Unit) by Type (2020-2025)

Table 59. Global Group A and Group C Meningococcal Polysaccharide Vaccine Price (US$/Unit) by Type (2026-2031)

Table 60. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units) by Application (2020-2025)

Table 61. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units) by Application (2026-2031)

Table 62. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2025)

Table 63. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2026-2031)

Table 64. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2020-2025)

Table 67. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2026-2031)

Table 68. Global Group A and Group C Meningococcal Polysaccharide Vaccine Price (US$/Unit) by Application (2020-2025)

Table 69. Global Group A and Group C Meningococcal Polysaccharide Vaccine Price (US$/Unit) by Application (2026-2031)

Table 70. Walvax Company Information

Table 71. Walvax Description and Business Overview

Table 72. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product

Table 74. Walvax Recent Developments/Updates

Table 75. Lanzhou Institute of Biological Products Company Information

Table 76. Lanzhou Institute of Biological Products Description and Business Overview

Table 77. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product

Table 79. Lanzhou Institute of Biological Products Recent Developments/Updates

Table 80. AIM Bio Company Information

Table 81. AIM Bio Description and Business Overview

Table 82. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product

Table 84. AIM Bio Recent Developments/Updates

Table 85. Sanofi Pasteur Company Information

Table 86. Sanofi Pasteur Description and Business Overview

Table 87. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product

Table 89. Sanofi Pasteur Recent Developments/Updates

Table 90. GSK Company Information

Table 91. GSK Description and Business Overview

Table 92. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product

Table 94. GSK Recent Developments/Updates

Table 95. Hualan Bio Company Information

Table 96. Hualan Bio Description and Business Overview

Table 97. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product

Table 99. Hualan Bio Recent Developments/Updates

Table 100. ZFSW Company Information

Table 101. ZFSW Description and Business Overview

Table 102. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product

Table 104. ZFSW Recent Developments/Updates

Table 105. Changsheng Company Information

Table 106. Changsheng Description and Business Overview

Table 107. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product

Table 109. Changsheng Recent Developments/Updates

Table 110. Kanghua Bio Company Information

Table 111. Kanghua Bio Description and Business Overview

Table 112. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product

Table 114. Kanghua Bio Recent Developments/Updates

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. Group A and Group C Meningococcal Polysaccharide Vaccine Distributors List

Table 118. Group A and Group C Meningococcal Polysaccharide Vaccine Customers List

Table 119. Group A and Group C Meningococcal Polysaccharide Vaccine Market Trends

Table 120. Group A and Group C Meningococcal Polysaccharide Vaccine Market Drivers

Table 121. Group A and Group C Meningococcal Polysaccharide Vaccine Market Challenges

Table 122. Group A and Group C Meningococcal Polysaccharide Vaccine Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Product Picture of Group A and Group C Meningococcal Polysaccharide Vaccine

Figure 2. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Share by Type: 2024 & 2031

Figure 4. Class 1 Vaccine Product Picture

Figure 5. Class II Vaccine Product Picture

Figure 6. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Share by Application: 2024 & 2031

Figure 8. Hospital

Figure 9. Clinic

Figure 10. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size (2020-2031) & (US$ Million)

Figure 12. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales (2020-2031) & (K Units)

Figure 13. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price (US$/Unit) & (2020-2031)

Figure 14. Group A and Group C Meningococcal Polysaccharide Vaccine Report Years Considered

Figure 15. Group A and Group C Meningococcal Polysaccharide Vaccine Sales Share by Manufacturers in 2024

Figure 16. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Share by Manufacturers in 2024

Figure 17. Global 5 and 10 Largest Group A and Group C Meningococcal Polysaccharide Vaccine Players: Market Share by Revenue in Group A and Group C Meningococcal Polysaccharide Vaccine in 2024

Figure 18. Group A and Group C Meningococcal Polysaccharide Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 19. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 20. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2020-2031)

Figure 21. North America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2020-2031)

Figure 22. United States Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 23. Canada Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2020-2031)

Figure 25. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2020-2031)

Figure 26. Germany Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. France Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. U.K. Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Italy Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Russia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2020-2031)

Figure 32. Asia Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2020-2031)

Figure 33. China Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Japan Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. South Korea Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. India Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Australia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. China Taiwan Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Southeast Asia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2020-2031)

Figure 41. Latin America Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2020-2031)

Figure 42. Mexico Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Brazil Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Argentina Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Colombia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2020-2031)

Figure 47. Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2020-2031)

Figure 48. Turkey Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. UAE Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Global Sales Market Share of Group A and Group C Meningococcal Polysaccharide Vaccine by Type (2020-2031)

Figure 52. Global Revenue Market Share of Group A and Group C Meningococcal Polysaccharide Vaccine by Type (2020-2031)

Figure 53. Global Group A and Group C Meningococcal Polysaccharide Vaccine Price (US$/Unit) by Type (2020-2031)

Figure 54. Global Sales Market Share of Group A and Group C Meningococcal Polysaccharide Vaccine by Application (2020-2031)

Figure 55. Global Revenue Market Share of Group A and Group C Meningococcal Polysaccharide Vaccine by Application (2020-2031)

Figure 56. Global Group A and Group C Meningococcal Polysaccharide Vaccine Price (US$/Unit) by Application (2020-2031)

Figure 57. Group A and Group C Meningococcal Polysaccharide Vaccine Value Chain

Figure 58. Channels of Distribution (Direct Vs Distribution)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions